Up to 50% of patients with melanoma have a genetic mutation in the BRAF gene leading to a hyperactivation of the MAPK signaling pathway and thus benefit from therapy with MAPK inhibitors (MAPKi; ref. 3). This evidence concerns the gene BRAF and melanoma.